According to Allgenesis Biotherapeutics, AG-8030 is a first-in-class, formyl peptide receptor (FPR) agonist formulated as an ...

CVD may interfere with an eye care provider’s ability to differentiate between choroidal melanoma and choroidal nevus ...

Yasha Modi, MD, spoke about the DAVIO phase 2 trial and the upcoming LUGANO phase 3 trial at the annual ASRS meeting in ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

As researchers unlock mysteries surrounding the caveolin-1 (CAV1) scaffolding protein in the cells of the trabecular meshwork ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Nathan Steinle, MD, spoke about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF ...

Eleonora Lad, MD, PhD, spoke about her presentation, "Multiwavelength photobiomodulation significantly reduces risk for ...

According to the company, OCU410 utilizes an adeno-associated virus platform for the retinal delivery of the RORA gene.

According to the company, the Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ...

AG-73305 is bi-specific, with anti-VEGF and anti-integrin. The dual mechanism of action has provided some interesting results ...

The collaboration agreement will allow the 2 companies to find a potential new treatment for chronic dry eye disease.